Showing 581-590 of 9049 results for "".
The Resurgence of Ablative Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-resurgence-of-ablative-devices/18620/E. Victor Ross, MD, talks to host Joel L. Cohen, MD about the resurgence of traditional ablative devices. Dr. Ross says he never abandoned full-face CO2 resurfacing, but explains the key is to titrate the settings down—doing confluent 100 percent coverage but low-depth one pass on the forehead and cCosmeceutical Advances in 2016
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmeceutical-advances-in-2016/18622/Suneel Chilukuri, MD discusses recent advances in the cosmeceutical market including a new topical formulated to protect the skin from UVA/UVB damage as well as from infrared radiation, a skin brightening topical formulated to carry retinol deeper into the skin, and a topical hyaluronic acid productPediatric Atopic Dermatitis And Psoriasis
https://practicaldermatology.com/topics/psoriasis/pediatric-atopic-dermatitis-and-psoriasis/18631/Lawrence Eichenfield, MD provides an update on pediatric atopic dermatitis and psoriasis. Unfortunately, he said, many children remain undertreated for their eczema despite the availability of effective treatments and a number of topical and systemic products on the horizon. Dr. Eichenfield also proAsk An Expert: Establishing Yourself as an Expert
https://practicaldermatology.com/topics/practice-management/ask-an-expert-establishing-yourself-as-an-expert/18937/In this edition of NewDermMD's video series, host Adam Friedman, MD speaks with Neal Bhatia, MD about establishing one's expertise, becoming an educator, and finding a comfortable place working with industry, peers, and societies. Whether your interest is in cosmetic dermatology, acne, psoriasis, peValeant Acquires Salix; Actavis Changing Name
https://practicaldermatology.com/series/dermwire-tv/valeant-acquires-salix-actavis-changing-name/18963/Valeant expands its portfolio with the acquisition of GI market leader Salix. Actavis divests Doryx and considers a name change to Allergan. Kythera acquires rights for investigational hair therapies. And Cynosure's 532nm laser delivery system is FDA cleared for PicoSure.Otezla Approved for Plaque Psoriasis
https://practicaldermatology.com/topics/psoriasis/dermiretv-otezla-approved-for-plaque-psoriasis/19031/In this week's edition of DermWireTV from the publishers of Practical Dermatology® magazine and DermWire.com, a look at Celgene's Otezla for psoriasis--the first PDE4 inhibitor approved for plaque psoriasis. Plus, Ranbaxy's new dosage strengths of Absorica (isotretinoin), and Galderma's search for pUpdate on Topical Acne Therapy for Adult Women
https://practicaldermatology.com/topics/general-topics/update-on-topical-acne-therapy-for-adult-women/19166/Diane Berson, MD, FAAD discusses the approach to management of acne in the adult female patient, emphasizing the role of vehicle to affect the patient experience, promote adherence, and optimize outcomes. Bonus Material: Hormonal Therapy for Female Acne Bonus Material: Procedures for Adult Female A"Atopic Dermatitis in Diverse Skin Tones" Drs. Shahriari and Bhutani
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/atopic-dermatitis-in-diverse-skin-tones-drs-shahriari-and-bhutani/24542/Drs. Mona Shahriari and Tina Bhutani provide a comprehensive overview of managing atopic dermatitis (AD) in patients with skin of color, addressing unique challenges and considerations. To access the full video and more, join YoungMD Connect member for free 90-day trial with code Free90. Continue leThe Role of Topical Steroids in AD
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37138/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, discusses the role of topical steroids in treating atopic dermatitis.Origins of AD: Recent Advances
https://practicaldermatology.com/issues/april-2025/origins-of-ad-recent-advances/35586/This paper reviews a study by Yadev et al. and further investigates the role of transient receptor potential ankyrin 1 (TRPA1) in the pathogenesis of atopic dermatitis (AD).